Quince Therapeutics (QNCX) Other Accumulated Expenses (2018 - 2026)

Quince Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (changed N/A YoY), while the FY2025 annual figure was $7.0 million, up 576.97% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.8 million, down from $7.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $7.0 million in Q4 2025, with the low at $41000.0 in Q3 2023.
• The 5-year median for Other Accumulated Expenses is $276000.0 (2023), against an average of $1.1 million.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses tumbled 98.36% in 2023, then surged 576.97% in 2025.
• Quince Therapeutics' Other Accumulated Expenses stood at $185000.0 in 2022, then soared by 38.92% to $257000.0 in 2023, then soared by 300.39% to $1.0 million in 2024, then soared by 576.97% to $7.0 million in 2025, then slumped by 74.85% to $1.8 million in 2026.
• Business Quant data shows QNCX's Other Accumulated Expenses at $1.8 million in Q1 2026, $7.0 million in Q4 2025, and $295000.0 in Q3 2025.